Abstract
Sulindac is a long-acting nonsteroidal anti-inflammatory drug (NSAID) widely used for the management of osteoarthritis, rheumatoid arthritis, ankylosing sponydlitis, and acute gouty arthritis. Reports of sulindac toxicity in the literature are rare. We report the case of a 22-year old male with a history of bipolar disorder who was brought to the emergency department after ingesting approximately 15 g of sulindac in a suicide attempt. He was found to have acute kidney injury and hyperbilirubinemia. Despite aggressive fluid resuscitation, his renal function progressively worsened requiring the initiation of hemodialysis. Ten days following ingestion of sulindac, he began to develop ischemic skin changes with a gangrenous appearance in his hands and feet. He continued to receive supportive treatment, and his acute kidney injury, hyperbillirubinemia, and ischemic skin necrosis eventually resolved. Clinicians should be aware of this long-acting NSAID and its ability to cause prolonged multisystem organ dysfunction.
Keywords: Clinoril, hepatotoxicity, nephrotoxicity, NSAID, overdose, sulindac.
Current Drug Safety
Title:Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose
Volume: 10 Issue: 2
Author(s): John L. Vaughn, Kejal V. Shah, Maroun M. Ghossein, William L. Meyer and Robert B. Kirkpatrick
Affiliation:
Keywords: Clinoril, hepatotoxicity, nephrotoxicity, NSAID, overdose, sulindac.
Abstract: Sulindac is a long-acting nonsteroidal anti-inflammatory drug (NSAID) widely used for the management of osteoarthritis, rheumatoid arthritis, ankylosing sponydlitis, and acute gouty arthritis. Reports of sulindac toxicity in the literature are rare. We report the case of a 22-year old male with a history of bipolar disorder who was brought to the emergency department after ingesting approximately 15 g of sulindac in a suicide attempt. He was found to have acute kidney injury and hyperbilirubinemia. Despite aggressive fluid resuscitation, his renal function progressively worsened requiring the initiation of hemodialysis. Ten days following ingestion of sulindac, he began to develop ischemic skin changes with a gangrenous appearance in his hands and feet. He continued to receive supportive treatment, and his acute kidney injury, hyperbillirubinemia, and ischemic skin necrosis eventually resolved. Clinicians should be aware of this long-acting NSAID and its ability to cause prolonged multisystem organ dysfunction.
Export Options
About this article
Cite this article as:
Vaughn L. John, Shah V. Kejal, Ghossein M. Maroun, Meyer L. William and Kirkpatrick B. Robert, Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose, Current Drug Safety 2015; 10 (2) . https://dx.doi.org/10.2174/157488631002150515150729
DOI https://dx.doi.org/10.2174/157488631002150515150729 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurodegeneration in the Pathogenesis of Diabetic Retinopathy: Molecular Mechanisms and Therapeutic Implications
Current Medicinal Chemistry Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design Skeletal Effects of Systemic and Topical Corticosteroids
Current Drug Safety Creating Chemical Diversity to Target Protein Kinases
Combinatorial Chemistry & High Throughput Screening Editorial [Stem Cell Applications and Tissue Engineering Approaches in Orthopaedic Surgery and Musculoskeletal Medicine (Guest Editor: Wasim S. Khan)]
Current Stem Cell Research & Therapy Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Lone Atrial Fibrillation- A Diagnosis of Exclusion
Current Pharmaceutical Design Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry Induction of Apoptotic Cell Death in Tumor Cells by S100A8/A9 Released from Inflammatory Cells Upon Cellular Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
Current Diabetes Reviews Biologics in Systemic Sclerosis
Current Pharmaceutical Biotechnology Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design Immunomodulatory Properties of ES-62, a Phosphorylcholine - Containing Glycoprotein Secreted by Acanthocheilonema viteae
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting C5a: Recent Advances in Drug Discovery
Current Medicinal Chemistry Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Can We Delay the Accelerated Lung Aging in COPD? Anti-Aging Molecules and Interventions
Current Drug Targets The Pharmacokinetics of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Circulating MicroRNAs as a New Class of Biomarkers of Physiological Reactions of the Organism to the Intake of Dietary Supplements and Drugs
MicroRNA Nerve Growth Factor: Early Studies and Recent Clinical Trials
Current Neuropharmacology